Charllote personal page - To The Moon

Charllote

Charllote

No personal profile

13Follow

31Followers

0Topic

0Badge

2022-06-27

its dun even count as asset, whereby value is judge based on investors, not products itself..[Happy] [Happy]

Sorry, the original content has been removed

2022-06-19

good and like

Sorry, the original content has been removed

2022-04-14

Gogoogog

Skittish Stock Traders Are Bracing for $2 Trillion Option Expiration

2021-12-30

Ok

DWAC: The SPAC Craze Is Over

2021-12-30

Ok

Sorry, the original content has been removed

2021-12-30

Ok

Biogen Dropped 5% in Premarket Trading

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3585210989099593","uuid":"3585210989099593","gmtCreate":1622647388502,"gmtModify":1630649717890,"name":"Charllote","pinyin":"charllote","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":31,"headSize":13,"tweetSize":19,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.12","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.93%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.07","exceedPercentage":"93.03%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9046139991,"gmtCreate":1656307439413,"gmtModify":1676535803653,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3585210989099593","authorIdStr":"3585210989099593"},"themes":[],"htmlText":"its dun even count as asset, whereby value is judge based on investors, not products itself..[Happy]&nbsp;[Happy]&nbsp;","listText":"its dun even count as asset, whereby value is judge based on investors, not products itself..[Happy]&nbsp;[Happy]&nbsp;","text":"its dun even count as asset, whereby value is judge based on investors, not products itself..[Happy] [Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9046139991","repostId":"1173489822","repostType":2,"isVote":1,"tweetType":1,"viewCount":423,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9040385427,"gmtCreate":1655609539369,"gmtModify":1676535671062,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3585210989099593","authorIdStr":"3585210989099593"},"themes":[],"htmlText":"good and like","listText":"good and like","text":"good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9040385427","repostId":"2244108696","repostType":2,"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9080407091,"gmtCreate":1649902566419,"gmtModify":1676534603298,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3585210989099593","authorIdStr":"3585210989099593"},"themes":[],"htmlText":"Gogoogog","listText":"Gogoogog","text":"Gogoogog","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9080407091","repostId":"1153344302","repostType":4,"repost":{"id":"1153344302","pubTimestamp":1649890579,"share":"https://ttm.financial/m/news/1153344302?lang=&edition=fundamental","pubTime":"2022-04-14 06:56","market":"us","language":"en","title":"Skittish Stock Traders Are Bracing for $2 Trillion Option Expiration","url":"https://stock-news.laohu8.com/highlight/detail?id=1153344302","media":"Bloomberg","summary":"BofA survey shows optimism about global growth at record lowIt’s not an easy time, particularly for ","content":"<html><head></head><body><ul><li>BofA survey shows optimism about global growth at record low</li><li>It’s not an easy time, particularly for stocks: Katy Kaminski</li></ul><p>Inflation is surging, central banks are on the move and now it’s earnings season. To top it all off, stock traders face the market-roiling potential of a monthly options expiration estimated at more than $2 trillion.</p><p>Roughly $495 billion in single-stock derivatives are set to expire Thursday, with another $980 billion of S&amp;P 500-linked contracts and $170 billion in options tied to the State Street fund tracking the S&amp;P 500 all running out as the holiday-shortened week ends, according to estimates from Goldman Sachs Group Inc.’s Rocky Fishman. Such volumes have been a source of volatility in the past year.</p><p>While nothing is ever assured in markets, indexes have exhibited a consistent pattern of declining on days when contracts are closed out. This time around, it comes as stocks are suffering through yet another bout of volatility, with the S&amp;P 500 notching only four positive days since the start of the month.</p><p>It isn’t out of the ordinary to get a monthly expiration on a Thursday in April, but other “wrinkles arise because it can coincide with tax day and the start of earnings season, both of which we’re getting now,” said Steve Sosnick, chief strategist at Interactive Brokers LLC. The deadline for Americans to file their tax returns is April 18.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/158c0f7e1238dc2a0511c55735fc17af\" tg-width=\"1000\" tg-height=\"685\" width=\"100%\" height=\"auto\"/><span>Source: Goldman SachsSource: Bloomberg</span></p><p>With monetary and fiscal support receding, investors have been hunkering down -- and the mood has turned gloomy. A survey by Bank of America Corp. showed fund-manager optimism about global growth is at a record low. The greatest number since 2008 are predicting a stagflationary period of lower growth and still-high inflation. Sentiment is “poor,” said the bank’s strategist. Managers remain in the “‘sell-the-rally’ camp,” and view previous selloffs as just an “appetizer.”</p><p>Others are dialing back their optimism. JPMorgan Chase &amp; Co.’s Marko Kolanovic, once a steadfast bull, said investors who previously raised stock holdings should now take profits and shift some money to government bonds. Truist Advisory Services’ Keith Lerner downgraded his view on equities, cutting them to neutral from attractive, while saying that the range of potential economic and market outcomes was “unusually wide.”</p><p>A cautious stance is prevalent in single-stock data, too. The 20-day average of Cboe’s put-call volume ratio for single stocks has risen from a four-month low, showing an increase in moves to hedge against price drops. Meanwhile, the Cboe Volatility Index, a gauge of prices on S&amp;P 500 options, has swung wildly this month, from as low as 18.6 to as high as 24.37. It was in the middle of that range as of 3:50 p.m. Wednesday.</p><p>“Given the backdrop of political uncertainty and supply-chain issues, I think it’s not an easy time, particularly for the equity markets,” Katy Kaminski, chief research strategist at AlphaSimplex, said in a phone interview. Inflation, for instance, “has more room to run than most people would like to think. They keep thinking everything is just going to go back to normal and I think it could take quite a while.”</p><p>Mushrooming options volume has been a regular feature of post-pandemic markets. Bullish options contracts became a favorite tool of retail traders who spent the Covid lockdowns trading from their phones. Now, amid choppier markets, demand for bearish options has been growing. Contracts tied to declines in State Street’s S&amp;P 500 ETF and the iShares iBoxx High Yield Corporate Bond ETF have started to rise again, with put open interest on the high-yield fund surging.</p><p>To be sure, Chris Murphy, co-head of derivatives strategy at Susquehanna International Group, said there is now likely to be less single-stock impact than in the day-trading frenzy of the past two years. Investors who bought puts in January and February when the market was selling off are way out of the money now, he said, which could mute the impact of expirations on market moves.</p><p>His team says a total of 85 million U.S.-listed option contracts are set to expire Thursday, an 8% decrease from a year ago. Single-stock contracts are down 12% year-over-year. “We are seeing a lot less of the meme stock trading compared to last year, that’s the major culprit,” Murphy said.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/16655cc222d21f0d71dd4257bfc5eae7\" tg-width=\"1000\" tg-height=\"682\" width=\"100%\" height=\"auto\"/><span>Source: Susquehanna, IVolatilitySource: Bloomberg</span></p><p>Meanwhile, index and ETF contracts increased 7% and 3%, respectively, versus year-earlier levels. “This is likely due to more of a focus on the macro environment and more hedging,” he said.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Skittish Stock Traders Are Bracing for $2 Trillion Option Expiration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSkittish Stock Traders Are Bracing for $2 Trillion Option Expiration\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-14 06:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-04-13/skittish-stock-traders-bracing-for-2-trillion-option-expiration?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BofA survey shows optimism about global growth at record lowIt’s not an easy time, particularly for stocks: Katy KaminskiInflation is surging, central banks are on the move and now it’s earnings ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-04-13/skittish-stock-traders-bracing-for-2-trillion-option-expiration?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.bloomberg.com/news/articles/2022-04-13/skittish-stock-traders-bracing-for-2-trillion-option-expiration?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153344302","content_text":"BofA survey shows optimism about global growth at record lowIt’s not an easy time, particularly for stocks: Katy KaminskiInflation is surging, central banks are on the move and now it’s earnings season. To top it all off, stock traders face the market-roiling potential of a monthly options expiration estimated at more than $2 trillion.Roughly $495 billion in single-stock derivatives are set to expire Thursday, with another $980 billion of S&P 500-linked contracts and $170 billion in options tied to the State Street fund tracking the S&P 500 all running out as the holiday-shortened week ends, according to estimates from Goldman Sachs Group Inc.’s Rocky Fishman. Such volumes have been a source of volatility in the past year.While nothing is ever assured in markets, indexes have exhibited a consistent pattern of declining on days when contracts are closed out. This time around, it comes as stocks are suffering through yet another bout of volatility, with the S&P 500 notching only four positive days since the start of the month.It isn’t out of the ordinary to get a monthly expiration on a Thursday in April, but other “wrinkles arise because it can coincide with tax day and the start of earnings season, both of which we’re getting now,” said Steve Sosnick, chief strategist at Interactive Brokers LLC. The deadline for Americans to file their tax returns is April 18.Source: Goldman SachsSource: BloombergWith monetary and fiscal support receding, investors have been hunkering down -- and the mood has turned gloomy. A survey by Bank of America Corp. showed fund-manager optimism about global growth is at a record low. The greatest number since 2008 are predicting a stagflationary period of lower growth and still-high inflation. Sentiment is “poor,” said the bank’s strategist. Managers remain in the “‘sell-the-rally’ camp,” and view previous selloffs as just an “appetizer.”Others are dialing back their optimism. JPMorgan Chase & Co.’s Marko Kolanovic, once a steadfast bull, said investors who previously raised stock holdings should now take profits and shift some money to government bonds. Truist Advisory Services’ Keith Lerner downgraded his view on equities, cutting them to neutral from attractive, while saying that the range of potential economic and market outcomes was “unusually wide.”A cautious stance is prevalent in single-stock data, too. The 20-day average of Cboe’s put-call volume ratio for single stocks has risen from a four-month low, showing an increase in moves to hedge against price drops. Meanwhile, the Cboe Volatility Index, a gauge of prices on S&P 500 options, has swung wildly this month, from as low as 18.6 to as high as 24.37. It was in the middle of that range as of 3:50 p.m. Wednesday.“Given the backdrop of political uncertainty and supply-chain issues, I think it’s not an easy time, particularly for the equity markets,” Katy Kaminski, chief research strategist at AlphaSimplex, said in a phone interview. Inflation, for instance, “has more room to run than most people would like to think. They keep thinking everything is just going to go back to normal and I think it could take quite a while.”Mushrooming options volume has been a regular feature of post-pandemic markets. Bullish options contracts became a favorite tool of retail traders who spent the Covid lockdowns trading from their phones. Now, amid choppier markets, demand for bearish options has been growing. Contracts tied to declines in State Street’s S&P 500 ETF and the iShares iBoxx High Yield Corporate Bond ETF have started to rise again, with put open interest on the high-yield fund surging.To be sure, Chris Murphy, co-head of derivatives strategy at Susquehanna International Group, said there is now likely to be less single-stock impact than in the day-trading frenzy of the past two years. Investors who bought puts in January and February when the market was selling off are way out of the money now, he said, which could mute the impact of expirations on market moves.His team says a total of 85 million U.S.-listed option contracts are set to expire Thursday, an 8% decrease from a year ago. Single-stock contracts are down 12% year-over-year. “We are seeing a lot less of the meme stock trading compared to last year, that’s the major culprit,” Murphy said.Source: Susquehanna, IVolatilitySource: BloombergMeanwhile, index and ETF contracts increased 7% and 3%, respectively, versus year-earlier levels. “This is likely due to more of a focus on the macro environment and more hedging,” he said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":597,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003975436,"gmtCreate":1640867568065,"gmtModify":1676533549171,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3585210989099593","authorIdStr":"3585210989099593"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003975436","repostId":"1161715768","repostType":4,"repost":{"id":"1161715768","pubTimestamp":1640866486,"share":"https://ttm.financial/m/news/1161715768?lang=&edition=fundamental","pubTime":"2021-12-30 20:14","market":"us","language":"en","title":"DWAC: The SPAC Craze Is Over","url":"https://stock-news.laohu8.com/highlight/detail?id=1161715768","media":"Seeking Alpha","summary":"SummaryDigital World Acquisition announced a merger deal with Trump Media & Technology Group in Octo","content":"<html><head></head><body><p><b>Summary</b></p><ul><li>Digital World Acquisition announced a merger deal with Trump Media &amp; Technology Group in October.</li><li>The new media company will go toe-to-toe with big technology companies including Twitter and Metaverse.</li><li>The initial Trump SPAC craze has faded and platform specifics are required to reduce investment risk.</li></ul><p>Two months ago,<b>Digital World Acquisition (DWAC)</b>announced a merger with Donald Trump&#39;s new media company, Trump Media &amp; Technology Group. The appeal of Donald Trump in the social media world is undeniable, but the SPAC should be avoided until strategy and product are clarified. While TMTG has lofty goals and intends to compete with top social media companies, there is far too much unknown at this point to justify the risk.</p><p><b>TMTG Got A Rocket Start</b></p><p>After the SPAC, a special type of acquisition company, announced a merger with Donald Trump&#39;s new social media company in October, Digital World Acquisition&#39;s share price skyrocketed by up to 1,500 percent. The merger announcement, on the other hand, was more than enough to get the stock moving.</p><p>Digital World Acquisition&#39;s stock skyrocketed after the SPAC deal was announced, reaching an all-time high of $175. The large increase in the company&#39;s market valuation drew comparisons to other meme stocks, such as <b>AMC (AMC)</b>and <b>GameStop (GME)</b>, which have also seen four-digit percentage gains.</p><p>However, DWAC stock has dropped significantly since then, indicating that the market is waiting for more information on how TMTG intends to monetize his likely large conservative-leaning following on his own social media network.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ea309f8a4ab8d76cb164bec409854081\" tg-width=\"640\" tg-height=\"267\" referrerpolicy=\"no-referrer\"/><span>Source: finviz</span></p><p><b>Creating A Competitor Social Media Network For Conservatives</b></p><p>Donald Trump&#39;s planned social media company is likely to attract a large conservative audience that has repeatedly complained about anti-conservative bias on platforms like <b>Twitter (TWTR)</b> or <b>Facebook (FB)</b>. A new social media network centered on Donald Trump would almost certainly attract a sizable number of followers. So, how large is the user opportunity for TMTG?</p><p>A look at the competition can aid in making high-level predictions. In 3Q21, Twitter had over 210 million active users, while Metaverse had 1.9 billion daily active users. Streaming behemoths Netflix(NASDAQ:NFLX)and Disney(NYSE:DIS)have 214 million and 116 million subscribers, respectively. TMTG will most likely want to participate in the growth of the streaming industry and capture some kind of subscription revenue. Before a ban was imposed in January 2021, Donald Trump had approximately 150 million followers on social media. With these figures in mind, 70-80 million followers/users are a reasonable target audience for Truth Social.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/00f3976e42707f2eda8c5a9771ab3a6d\" tg-width=\"640\" tg-height=\"311\" referrerpolicy=\"no-referrer\"/><span>Source: TMTG Company</span></p><p>TMTG will most likely want to dabble in several business lines at the same time. It could provide news, paid subscription content, podcasts, and an ad-supported messaging platform. The end result could be a social media company that combines Twitter, YouTube(NASDAQ:GOOG)(NASDAQ:GOOGL), Spotify(NYSE:SPOT), and Netflix. With an estimated 70-80 million users, TMTG has the potential to become a major player in the conservative media market.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/51b545fad14d50ca5d02aeb2aaf5eea8\" tg-width=\"640\" tg-height=\"335\" referrerpolicy=\"no-referrer\"/><span>Source: TMTG Company</span></p><p><b>How Big Could Donald Trump’s New Media Empire Become?</b></p><p>Big, theoretically. Before deleting his accounts in 2021, Donald Trump had nearly 90 million followers on Twitter alone. He received 74 million votes, so I would expect Mr. Trump&#39;s social media platform to have at least 70 million users from the United States alone, not counting users from other countries. In a more optimistic scenario, the social media company could have 100 million users, many of whom are monetizable.</p><p>TMTG projections calculate with 81 million users by 2026 could deliver up to $3.7 billion in revenues.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eea849a6a0f819d6da35ab2f17f7c900\" tg-width=\"640\" tg-height=\"319\" referrerpolicy=\"no-referrer\"/><span>Source: TMTG Company</span></p><p>Given Mr. Trump&#39;s clout in the Republican Party and among conservatives, TMTG is an intriguing play and, once the platform is available, likely the most exciting new kid on the block. The value proposition of TMTG is at least interesting, depending on the monetization model pursued by TMTG and the number of users the platform could attract. Furthermore, TMTG has secured $1 billion in committed capital for the development of Truth Social.</p><p><b>Why I Am Not Buying DWAC Anytime Soon</b></p><p>While there is certainly room for a conservative-leaning media company, launching a new social media network is not easy. Also, there is currently little more than an investor presentation available, and before deciding to buy a stock, I like to see the finished product. Nothing compels me to buy the stock until Truth Social goes live next year and we see what the platform actually looks like and how much traction it gets. Purchasing DWAC at this point is akin to purchasing a car before ever seeing or driving it.</p><p>Second, DWAC is being investigated by the SEC, which is looking into how the SPAC deal unfolded. As an unproven social media company, the investigation adds to DWAC&#39;s considerable risks.</p><p><b>My Conclusion</b></p><p>TMTG has a lot of potential to build a conservative-leaning social media network, but the risk/reward trade-off is currently unappealing. Too many details are unknown, such as how the new social media platform will look and how the company intends to monetize its users. In addition, the initial SPAC craze has subsided. Mr. Trump&#39;s SPAC is not yet a buy unless specifics and platform details are released.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DWAC: The SPAC Craze Is Over</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDWAC: The SPAC Craze Is Over\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 20:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4477278-dwac-the-spac-craze-is-over><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryDigital World Acquisition announced a merger deal with Trump Media & Technology Group in October.The new media company will go toe-to-toe with big technology companies including Twitter and ...</p>\n\n<a href=\"https://seekingalpha.com/article/4477278-dwac-the-spac-craze-is-over\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/article/4477278-dwac-the-spac-craze-is-over","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161715768","content_text":"SummaryDigital World Acquisition announced a merger deal with Trump Media & Technology Group in October.The new media company will go toe-to-toe with big technology companies including Twitter and Metaverse.The initial Trump SPAC craze has faded and platform specifics are required to reduce investment risk.Two months ago,Digital World Acquisition (DWAC)announced a merger with Donald Trump's new media company, Trump Media & Technology Group. The appeal of Donald Trump in the social media world is undeniable, but the SPAC should be avoided until strategy and product are clarified. While TMTG has lofty goals and intends to compete with top social media companies, there is far too much unknown at this point to justify the risk.TMTG Got A Rocket StartAfter the SPAC, a special type of acquisition company, announced a merger with Donald Trump's new social media company in October, Digital World Acquisition's share price skyrocketed by up to 1,500 percent. The merger announcement, on the other hand, was more than enough to get the stock moving.Digital World Acquisition's stock skyrocketed after the SPAC deal was announced, reaching an all-time high of $175. The large increase in the company's market valuation drew comparisons to other meme stocks, such as AMC (AMC)and GameStop (GME), which have also seen four-digit percentage gains.However, DWAC stock has dropped significantly since then, indicating that the market is waiting for more information on how TMTG intends to monetize his likely large conservative-leaning following on his own social media network.Source: finvizCreating A Competitor Social Media Network For ConservativesDonald Trump's planned social media company is likely to attract a large conservative audience that has repeatedly complained about anti-conservative bias on platforms like Twitter (TWTR) or Facebook (FB). A new social media network centered on Donald Trump would almost certainly attract a sizable number of followers. So, how large is the user opportunity for TMTG?A look at the competition can aid in making high-level predictions. In 3Q21, Twitter had over 210 million active users, while Metaverse had 1.9 billion daily active users. Streaming behemoths Netflix(NASDAQ:NFLX)and Disney(NYSE:DIS)have 214 million and 116 million subscribers, respectively. TMTG will most likely want to participate in the growth of the streaming industry and capture some kind of subscription revenue. Before a ban was imposed in January 2021, Donald Trump had approximately 150 million followers on social media. With these figures in mind, 70-80 million followers/users are a reasonable target audience for Truth Social.Source: TMTG CompanyTMTG will most likely want to dabble in several business lines at the same time. It could provide news, paid subscription content, podcasts, and an ad-supported messaging platform. The end result could be a social media company that combines Twitter, YouTube(NASDAQ:GOOG)(NASDAQ:GOOGL), Spotify(NYSE:SPOT), and Netflix. With an estimated 70-80 million users, TMTG has the potential to become a major player in the conservative media market.Source: TMTG CompanyHow Big Could Donald Trump’s New Media Empire Become?Big, theoretically. Before deleting his accounts in 2021, Donald Trump had nearly 90 million followers on Twitter alone. He received 74 million votes, so I would expect Mr. Trump's social media platform to have at least 70 million users from the United States alone, not counting users from other countries. In a more optimistic scenario, the social media company could have 100 million users, many of whom are monetizable.TMTG projections calculate with 81 million users by 2026 could deliver up to $3.7 billion in revenues.Source: TMTG CompanyGiven Mr. Trump's clout in the Republican Party and among conservatives, TMTG is an intriguing play and, once the platform is available, likely the most exciting new kid on the block. The value proposition of TMTG is at least interesting, depending on the monetization model pursued by TMTG and the number of users the platform could attract. Furthermore, TMTG has secured $1 billion in committed capital for the development of Truth Social.Why I Am Not Buying DWAC Anytime SoonWhile there is certainly room for a conservative-leaning media company, launching a new social media network is not easy. Also, there is currently little more than an investor presentation available, and before deciding to buy a stock, I like to see the finished product. Nothing compels me to buy the stock until Truth Social goes live next year and we see what the platform actually looks like and how much traction it gets. Purchasing DWAC at this point is akin to purchasing a car before ever seeing or driving it.Second, DWAC is being investigated by the SEC, which is looking into how the SPAC deal unfolded. As an unproven social media company, the investigation adds to DWAC's considerable risks.My ConclusionTMTG has a lot of potential to build a conservative-leaning social media network, but the risk/reward trade-off is currently unappealing. Too many details are unknown, such as how the new social media platform will look and how the company intends to monetize its users. In addition, the initial SPAC craze has subsided. Mr. Trump's SPAC is not yet a buy unless specifics and platform details are released.","news_type":1},"isVote":1,"tweetType":1,"viewCount":389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003928423,"gmtCreate":1640856403288,"gmtModify":1676533548278,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3585210989099593","authorIdStr":"3585210989099593"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003928423","repostId":"2195454191","repostType":4,"isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003928283,"gmtCreate":1640856376009,"gmtModify":1676533548262,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3585210989099593","authorIdStr":"3585210989099593"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003928283","repostId":"1198596106","repostType":4,"repost":{"id":"1198596106","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640855595,"share":"https://ttm.financial/m/news/1198596106?lang=&edition=fundamental","pubTime":"2021-12-30 17:13","market":"us","language":"en","title":"Biogen Dropped 5% in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1198596106","media":"Tiger Newspress","summary":"U.S. drugmaker Biogen Inc dropped 5% in premarket trading, as Samsung Biologics denied report saying","content":"<html><head></head><body><p>U.S. drugmaker Biogen Inc dropped 5% in premarket trading, as Samsung Biologics denied report saying Samsung in talks to acquire Biogen.<img src=\"https://static.tigerbbs.com/0d21708fdbb17a292f7748f78750b030\" tg-width=\"1121\" tg-height=\"718\" referrerpolicy=\"no-referrer\"/>Samsung BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc.</p><p>Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen had approached Samsung to buy its shares, which could be valued at more than $42 billion. Biogen is valued at $34.67 billion, according to Refinitiv data.</p><p>Samsung BioLogics, the biotech unit of Samsung Group, said in a regulatory filing that the report was &#34;not true,&#34; without giving any more details.</p><p>Biogen said it does not comment on market rumors or speculation. Its stock closed up 9.5% on Wednesday.</p><p>Any such deal would be the biggest overseas acquisition ever by a South Korean company. The largest so far was in 2016, when Samsung Electronics bought auto electronics maker Harman International Industries in an $8 billion deal.</p><p>Samsung Group had said earlier this year it will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era.</p><p>In June, Biogen&#39;s controversial Alzheimer&#39;s drug won U.S. regulatory approval, becoming the first new treatment for the memory-robbing disease in nearly 20 years, despite an outside advisory panel&#39;s view that the company had not proven the treatment&#39;s clinical benefits.</p><p>Biogen has been betting on the drug, Aduhelm, to buffer a hit as its main revenue drivers such as multiple sclerosis treatment Tecfidera and muscle disease treatment Spinraza face rising competition.</p><p>But U.S. sales from Aduhelm have been slower than expected as hospitals complained that the drug&#39;s high cost was not worth its benefits. The company cut its price by about half to $28,200 this month.</p><p>Biogen, which makes drugs for neurological diseases, currently has more than 30 new drugs in its pipeline.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Dropped 5% in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Dropped 5% in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-30 17:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>U.S. drugmaker Biogen Inc dropped 5% in premarket trading, as Samsung Biologics denied report saying Samsung in talks to acquire Biogen.<img src=\"https://static.tigerbbs.com/0d21708fdbb17a292f7748f78750b030\" tg-width=\"1121\" tg-height=\"718\" referrerpolicy=\"no-referrer\"/>Samsung BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc.</p><p>Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen had approached Samsung to buy its shares, which could be valued at more than $42 billion. Biogen is valued at $34.67 billion, according to Refinitiv data.</p><p>Samsung BioLogics, the biotech unit of Samsung Group, said in a regulatory filing that the report was &#34;not true,&#34; without giving any more details.</p><p>Biogen said it does not comment on market rumors or speculation. Its stock closed up 9.5% on Wednesday.</p><p>Any such deal would be the biggest overseas acquisition ever by a South Korean company. The largest so far was in 2016, when Samsung Electronics bought auto electronics maker Harman International Industries in an $8 billion deal.</p><p>Samsung Group had said earlier this year it will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era.</p><p>In June, Biogen&#39;s controversial Alzheimer&#39;s drug won U.S. regulatory approval, becoming the first new treatment for the memory-robbing disease in nearly 20 years, despite an outside advisory panel&#39;s view that the company had not proven the treatment&#39;s clinical benefits.</p><p>Biogen has been betting on the drug, Aduhelm, to buffer a hit as its main revenue drivers such as multiple sclerosis treatment Tecfidera and muscle disease treatment Spinraza face rising competition.</p><p>But U.S. sales from Aduhelm have been slower than expected as hospitals complained that the drug&#39;s high cost was not worth its benefits. The company cut its price by about half to $28,200 this month.</p><p>Biogen, which makes drugs for neurological diseases, currently has more than 30 new drugs in its pipeline.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198596106","content_text":"U.S. drugmaker Biogen Inc dropped 5% in premarket trading, as Samsung Biologics denied report saying Samsung in talks to acquire Biogen.Samsung BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc.Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen had approached Samsung to buy its shares, which could be valued at more than $42 billion. Biogen is valued at $34.67 billion, according to Refinitiv data.Samsung BioLogics, the biotech unit of Samsung Group, said in a regulatory filing that the report was \"not true,\" without giving any more details.Biogen said it does not comment on market rumors or speculation. Its stock closed up 9.5% on Wednesday.Any such deal would be the biggest overseas acquisition ever by a South Korean company. The largest so far was in 2016, when Samsung Electronics bought auto electronics maker Harman International Industries in an $8 billion deal.Samsung Group had said earlier this year it will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era.In June, Biogen's controversial Alzheimer's drug won U.S. regulatory approval, becoming the first new treatment for the memory-robbing disease in nearly 20 years, despite an outside advisory panel's view that the company had not proven the treatment's clinical benefits.Biogen has been betting on the drug, Aduhelm, to buffer a hit as its main revenue drivers such as multiple sclerosis treatment Tecfidera and muscle disease treatment Spinraza face rising competition.But U.S. sales from Aduhelm have been slower than expected as hospitals complained that the drug's high cost was not worth its benefits. The company cut its price by about half to $28,200 this month.Biogen, which makes drugs for neurological diseases, currently has more than 30 new drugs in its pipeline.","news_type":1},"isVote":1,"tweetType":1,"viewCount":152,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9080407091,"gmtCreate":1649902566419,"gmtModify":1676534603298,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3585210989099593","authorIdStr":"3585210989099593"},"themes":[],"htmlText":"Gogoogog","listText":"Gogoogog","text":"Gogoogog","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9080407091","repostId":"1153344302","repostType":4,"isVote":1,"tweetType":1,"viewCount":597,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003975436,"gmtCreate":1640867568065,"gmtModify":1676533549171,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3585210989099593","authorIdStr":"3585210989099593"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003975436","repostId":"1161715768","repostType":4,"isVote":1,"tweetType":1,"viewCount":389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003928283,"gmtCreate":1640856376009,"gmtModify":1676533548262,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3585210989099593","authorIdStr":"3585210989099593"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003928283","repostId":"1198596106","repostType":4,"isVote":1,"tweetType":1,"viewCount":152,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9046139991,"gmtCreate":1656307439413,"gmtModify":1676535803653,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3585210989099593","authorIdStr":"3585210989099593"},"themes":[],"htmlText":"its dun even count as asset, whereby value is judge based on investors, not products itself..[Happy]&nbsp;[Happy]&nbsp;","listText":"its dun even count as asset, whereby value is judge based on investors, not products itself..[Happy]&nbsp;[Happy]&nbsp;","text":"its dun even count as asset, whereby value is judge based on investors, not products itself..[Happy] [Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9046139991","repostId":"1173489822","repostType":2,"repost":{"id":"1173489822","pubTimestamp":1656287920,"share":"https://ttm.financial/m/news/1173489822?lang=&edition=fundamental","pubTime":"2022-06-27 07:58","market":"fut","language":"en","title":"Crypto Stocks Show Why They’re Among the Riskiest of Risk Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=1173489822","media":"Bloomberg","summary":"Sector selloff is worse than meme meltdown and SPAC slumpLimited exposure strategy comes back to hau","content":"<html><head></head><body><ul><li>Sector selloff is worse than meme meltdown and SPAC slump</li><li>Limited exposure strategy comes back to haunt investors</li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3d286898d0b104f9857379f7524f9154\" tg-width=\"1000\" tg-height=\"666\" width=\"100%\" height=\"auto\"/><span>Photographer: Michael Nagle/Bloomberg</span></p><p>Crypto curious stock investors are taking little comfort in the rebound in the shares of companies linked to the digital-asset world in the past week, with the sector underperforming just about every other risky corner of the financial markets this year by a wide margin.</p><p>Coinbase Global Inc., touted last year as one of the best ways to gain exposure to crypto when it was first listed on Nasdaq, has tumbled 75% since December. MicroStategy Inc. is down 62%, or more than Bitcoin, for which the software company has been seen a proxy for since Chief Executive Michael Saylor loaded up its balance sheet with the coins. Digital token mining leaders Marathon Digital Holdings Inc. andRiot Blockchain Inc. are down similar amounts, while smaller rivals such as Strong hold Digital Mining Inc. having plunged even more.</p><p>As the second-quarter winds down, cryptocurrency-related stocks are being lumped in with the digital tokens as one of the world’s riskiest asset classes. The NYSE FactSet Global Blockchain Technologies Index has fallen 65% this year, underperforming not only Bitcoin, but also an index that tracks highly volatile so-called meme stocks as well as a gauge of special purpose acquisition vehicle names.</p><p>Crypto stocks are “essentially a leveraged bet on one of the riskiest risk assets that there is,” said Steve Sosnick, chief strategist at Interactive Brokers LLC. He added that there are only a few other bets that he’d considered a higher risk for investors including certain meme and penny stocks.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d69cf155cfce2ee95b32539b0682a9b6\" tg-width=\"930\" tg-height=\"523\" width=\"100%\" height=\"auto\"/><span>Bloomberg</span></p><p>While outsized drawdowns by Bitcoin are nothing new across its roughly 12-year history, the most recent selloff has been particularly brutal given the scope of the losses seen across the broader crypto industry. In less than six months, the crypto market has seen more than $1 trillion in value erased, with an index of the 100 largest digital assets sinking about 59% and on pace for its worst year since the prior bear market in 2018.</p><p>The selloff in crypto names, which started in early November after Bitcoin hit an all-time high of almost $69,000, has accelerated this year as investors globally began to rotate out of riskier assets classes amid fears that a batch of aggressive rate hikes by the Federal Reserve aimed at cooling inflation would plunge the US economy into a recession. Further adding to the pain for investors was the May implosion of the Terra/Luna ecosystem which set off a series of liquidations across the industry and sparked a rash of panic selling.</p><p>Despite the risks and deeply depressed share prices, Wall Street analysts have largely remained optimistic on the vast majority of crypto-exposed stocks.</p><p>Coinbase, which has lost more than $60 billion in value since hitting a record high in November, currently has 20 buy recommendations, according to data compiled by Bloomberg. Thats the exact same number it had back in early January, when the stock was worth more than triple its current value.</p><p>“While we are not at all dismissive of the impact of the current crypto market downturn, we also believe any notion that Coinbase would be unable to survive this latest challenge is misguided in light of the facts on the ground,” according to BTIG analyst Mark Palmer who this week cut his price target on the stock to $290, down from a Street-high $380. It closed Friday at $62.71, after rebounding 22% this week.</p><p>Other crypto stocks have seen similarly bullish dedication from the analyst community. Bitcoin miners Riot Blockchain and Marathon Digital each have at least 75% buy-equivalent ratings and sport average 12-month price targets that are roughly 379% and 293% respectively above their current share prices.</p><p>They’re not alone either. Among the 33 stocks that make up the NYSE FactSet Global Blockchain Technologies Index, the average projected return over the next year is nearly 200%, over five times higher than the average across the Nasdaq 100 Index.</p><p><img src=\"https://static.tigerbbs.com/26974d5f35fd751dca1c9a20babceb19\" tg-width=\"976\" tg-height=\"543\" width=\"100%\" height=\"auto\"/></p><p>To be sure, the largely positive long-term outlook for the cryptocurrency market doesn’t come without caveats.</p><p>“We remain skeptical that crypto prices are fully out of the woods,” said Compass Point analyst Chris Allen. “We could see more downside to come given the uncertainty of Celsius/3AC insolvency situation and the pending asset sales that will likely result.”</p><p>One particularly troubling sign for investors looking to buy the dip in crypto stocks, despite the already historically deep selloff by some names, stocks like Voyager Digital Ltd. have proved that there is always room to fall further.</p><p>Shares of the cryptocurrency brokerage firm sank by 53% on Wednesday, the most since 2001, after it said it may issue a notice of default to hedge fund Three Arrows Capital Ltd. over its failure to repay a loan worth roughly $660 million. Before that plunge, the stock had already lost roughly 90% of its value this year.</p><p>“Given the size of the exposure, and given the uncertainty with respect to Voyager’s collecting on any of these balances, we believe it is difficult to arrive at a reasonable estimate of Voyager’s equity value per share,” KBW analyst Kyle Voigt wrote in a note after removing his outperform rating on the stock.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto Stocks Show Why They’re Among the Riskiest of Risk Assets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto Stocks Show Why They’re Among the Riskiest of Risk Assets\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-27 07:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-06-26/crypto-stocks-show-why-they-re-among-the-riskiest-of-risk-assets><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sector selloff is worse than meme meltdown and SPAC slumpLimited exposure strategy comes back to haunt investorsPhotographer: Michael Nagle/BloombergCrypto curious stock investors are taking little ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-06-26/crypto-stocks-show-why-they-re-among-the-riskiest-of-risk-assets\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VYGVF":"Voyager Digital Ltd.","COIN":"Coinbase Global, Inc.","BTBT":"Bit Digital, Inc.","MARA":"Marathon Digital Holdings Inc","RIOT":"Riot Platforms"},"source_url":"https://www.bloomberg.com/news/articles/2022-06-26/crypto-stocks-show-why-they-re-among-the-riskiest-of-risk-assets","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173489822","content_text":"Sector selloff is worse than meme meltdown and SPAC slumpLimited exposure strategy comes back to haunt investorsPhotographer: Michael Nagle/BloombergCrypto curious stock investors are taking little comfort in the rebound in the shares of companies linked to the digital-asset world in the past week, with the sector underperforming just about every other risky corner of the financial markets this year by a wide margin.Coinbase Global Inc., touted last year as one of the best ways to gain exposure to crypto when it was first listed on Nasdaq, has tumbled 75% since December. MicroStategy Inc. is down 62%, or more than Bitcoin, for which the software company has been seen a proxy for since Chief Executive Michael Saylor loaded up its balance sheet with the coins. Digital token mining leaders Marathon Digital Holdings Inc. andRiot Blockchain Inc. are down similar amounts, while smaller rivals such as Strong hold Digital Mining Inc. having plunged even more.As the second-quarter winds down, cryptocurrency-related stocks are being lumped in with the digital tokens as one of the world’s riskiest asset classes. The NYSE FactSet Global Blockchain Technologies Index has fallen 65% this year, underperforming not only Bitcoin, but also an index that tracks highly volatile so-called meme stocks as well as a gauge of special purpose acquisition vehicle names.Crypto stocks are “essentially a leveraged bet on one of the riskiest risk assets that there is,” said Steve Sosnick, chief strategist at Interactive Brokers LLC. He added that there are only a few other bets that he’d considered a higher risk for investors including certain meme and penny stocks.BloombergWhile outsized drawdowns by Bitcoin are nothing new across its roughly 12-year history, the most recent selloff has been particularly brutal given the scope of the losses seen across the broader crypto industry. In less than six months, the crypto market has seen more than $1 trillion in value erased, with an index of the 100 largest digital assets sinking about 59% and on pace for its worst year since the prior bear market in 2018.The selloff in crypto names, which started in early November after Bitcoin hit an all-time high of almost $69,000, has accelerated this year as investors globally began to rotate out of riskier assets classes amid fears that a batch of aggressive rate hikes by the Federal Reserve aimed at cooling inflation would plunge the US economy into a recession. Further adding to the pain for investors was the May implosion of the Terra/Luna ecosystem which set off a series of liquidations across the industry and sparked a rash of panic selling.Despite the risks and deeply depressed share prices, Wall Street analysts have largely remained optimistic on the vast majority of crypto-exposed stocks.Coinbase, which has lost more than $60 billion in value since hitting a record high in November, currently has 20 buy recommendations, according to data compiled by Bloomberg. Thats the exact same number it had back in early January, when the stock was worth more than triple its current value.“While we are not at all dismissive of the impact of the current crypto market downturn, we also believe any notion that Coinbase would be unable to survive this latest challenge is misguided in light of the facts on the ground,” according to BTIG analyst Mark Palmer who this week cut his price target on the stock to $290, down from a Street-high $380. It closed Friday at $62.71, after rebounding 22% this week.Other crypto stocks have seen similarly bullish dedication from the analyst community. Bitcoin miners Riot Blockchain and Marathon Digital each have at least 75% buy-equivalent ratings and sport average 12-month price targets that are roughly 379% and 293% respectively above their current share prices.They’re not alone either. Among the 33 stocks that make up the NYSE FactSet Global Blockchain Technologies Index, the average projected return over the next year is nearly 200%, over five times higher than the average across the Nasdaq 100 Index.To be sure, the largely positive long-term outlook for the cryptocurrency market doesn’t come without caveats.“We remain skeptical that crypto prices are fully out of the woods,” said Compass Point analyst Chris Allen. “We could see more downside to come given the uncertainty of Celsius/3AC insolvency situation and the pending asset sales that will likely result.”One particularly troubling sign for investors looking to buy the dip in crypto stocks, despite the already historically deep selloff by some names, stocks like Voyager Digital Ltd. have proved that there is always room to fall further.Shares of the cryptocurrency brokerage firm sank by 53% on Wednesday, the most since 2001, after it said it may issue a notice of default to hedge fund Three Arrows Capital Ltd. over its failure to repay a loan worth roughly $660 million. Before that plunge, the stock had already lost roughly 90% of its value this year.“Given the size of the exposure, and given the uncertainty with respect to Voyager’s collecting on any of these balances, we believe it is difficult to arrive at a reasonable estimate of Voyager’s equity value per share,” KBW analyst Kyle Voigt wrote in a note after removing his outperform rating on the stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":423,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9040385427,"gmtCreate":1655609539369,"gmtModify":1676535671062,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3585210989099593","authorIdStr":"3585210989099593"},"themes":[],"htmlText":"good and like","listText":"good and like","text":"good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9040385427","repostId":"2244108696","repostType":2,"repost":{"id":"2244108696","pubTimestamp":1655599329,"share":"https://ttm.financial/m/news/2244108696?lang=&edition=fundamental","pubTime":"2022-06-19 08:42","market":"us","language":"en","title":"Nasdaq Bear Market: 4 Remarkable Growth Stocks You'll Regret Not Buying on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2244108696","media":"Motley Fool","summary":"These fast-paced companies are ripe for the picking following a peak decline of 33% for the Nasdaq.","content":"<html><head></head><body><p>This year has offered a not-so-subtle reminder to Wall Street and the investing community that stocks don&#39;t move upward in a straight line. Since hitting their all-time closing highs, the widely followed <b>Dow Jones Industrial Average</b>, benchmark <b>S&amp;P 500</b>, and growth stock-fueled <b>Nasdaq Composite</b> (^IXIC 1.43%) have respectively tumbled by 17%, 22%, and 33%. These moves squarely put the S&amp;P 500 and Nasdaq in a bear market.</p><p>There&#39;s no question that the velocity and unpredictability of downward moves during a bear market can weigh on investors&#39; psyche. However, it&#39;s important to note that every notable decline in the major U.S. indexes, including the Nasdaq Composite, has eventually been cleared away by a bull market. This makes corrections and bear markets the opportune time to put your money to work.</p><p><img src=\"https://static.tigerbbs.com/bfa6ff2b91c8f20bca964751a738928f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>With the Nasdaq tumbling, a number of innovative growth stocks now look like incredible deals. What follows are four remarkable growth stocks you&#39;ll regret not buying on the dip.</p><h2><a href=\"https://laohu8.com/S/SQ\">Block</a></h2><p>The first exceptionally innovative company investors can confidently buy during the Nasdaq bear market decline is fintech stock <b>Block</b> (SQ 1.74%), the company formerly known as Square. Although cryptocurrency weakness could hurt <b>Bitcoin</b> trading revenue in the near term, and high inflation is bad news for low-income consumers, there are more than enough long-term catalysts for Block to deliver jaw-dropping growth.</p><p>For more than a decade, the company&#39;s foundation has been its seller ecosystem, commonly referred to as the &#34;Square ecosystem.&#34; This is the segment that provides point-of-sale solutions, loans, and analytics to businesses to help them succeed. In 2012, just $6.5 billion in gross payment volume (GPV) was processed by the Square ecosystem. But based on the $39.5 billion in GPV in during the first quarter of 2022, the Square ecosystem is on pace for $158 billion in annual GPV.</p><p>What&#39;s particularly interesting about the seller ecosystem is that it&#39;s attracting bigger businesses that have higher annualized GPVs. Since this is predominantly a fee-driven operating segment, bigger business should lead to higher gross profit.</p><p>The other key for Block is digital peer-to-peer payment platform Cash App. In the four years between the end of 2017 and end of 2021, the number of monthly transacting users on Cash App soared from 7 million to north of 44 million. With the recent acquisition of buy now, pay later company Afterpay, Block has the ability to create a closed-loop payment network with its Square ecosystem.</p><h2>Airbnb</h2><p>A second remarkable growth stock that you&#39;ll be kicking yourself if you don&#39;t buy on this Nasdaq bear market decline is travel and hosting company <b>Airbnb</b> (ABNB 6.68%). Even with recession fears rising and inflation biting consumers&#39; wallets hard in the short term, Airbnb has &#34;industry disruptor&#34; written all over it.</p><p>To begin with, Airbnb is unquestionably a popular alternative to traditional hotels. The Airbnb marketplace provides abundant choice, with properties that often provide a lower cost and added privacy, compared to staying in a hotel in or near a major city. In 2016, the entire platform recognized 52 million total nights and experiences booked. In just the first quarter of 2022, Airbnb practically doubled this figure, with 102.1 million nights and experiences booked.</p><p>Arguably the most exciting thing about Airbnb is that long-term stays are its fastest-growing category. A &#34;long-term stay&#34; is defined as a booking of 28 or more days. In the wake of the pandemic, we&#39;ve witnessed workforces becoming more mobile. These remote workers seem to be Airbnb&#39;s key to sustainably growing its hosting marketplace.</p><p>Additionally, the company wants a larger piece of the $8 trillion travel industry pie. Airbnb&#39;s &#34;experiences&#34; segment is working with local experts to lead travelers on adventures, and is likely just scratching the surface with regard to its partnership potential.</p><p><img src=\"https://static.tigerbbs.com/1250c39a18ffc461acf59040018e7def\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>Intuitive Surgical</h2><p>Another sensational growth stock investors would be wise to scoop up on the Nasdaq bear market dip is robotic-assisted surgical system developer <b>Intuitive Surgical</b> (ISRG 0.72%).</p><p>One reason for investors to trust Intuitive Surgical over the long haul is its market dominance. When the first quarter came to a close, the company had 6,920 of its da Vinci surgical systems installed in hospitals and surgical centers worldwide. This number may not sound like a lot, but it&#39;s <i>many</i> times higher than those of its closest competitors. What&#39;s more, these systems are costly ($0.5 million to $2.5 million) and the training for them is time-consuming. In other words, da Vinci buyers tend to remain clients for a long time.</p><p>Intuitive Surgical&#39;s razor-and-blades operating model is also designed to emphasize operating-margin growth over time. During the 2000s, most of the company&#39;s sales originated from selling its pricey, but generally low-margin, da Vinci systems. Nowadays, instruments sold with each procedure and system servicing account for the lion&#39;s share of total sales. These are higher-margin operating segments. As the company&#39;s installed base of systems grows, profits should increase at an even faster pace.</p><p>There&#39;s also a long runway for da Vinci to become a standard of care in the operating room. While it&#39;s already a leader in urology and gynecology procedures, there&#39;s plenty of room for expansion in colorectal, thoracic, and general soft-tissue surgical procedures.</p><h2>Upstart Holdings</h2><p>A fourth and final remarkable growth stock that you&#39;ll regret not buying on the dip is cloud-based lending platform <b>Upstart Holdings</b> (UPST 9.54%). Even though Wall Street is leery of the unproven Upstart as interest rates rise and fears of a U.S. recession grow, there are multiple aspects of the company&#39;s operating model that suggest it could thrive.</p><p>Perhaps the biggest differentiator for Upstart is its artificial intelligence (AI)-powered lending platform. Rather than relying on the same vetting process for loans that financial institutions have leaned on for decades, Upstart uses AI. This led to 74% of all loans on its platform being fully automated during the first quarter. Automation ultimately saves financial institutions time and money.</p><p>To build on this point, Upstart&#39;s AI-fueled lending platform is opening up opportunities for previously underbanked people. Although the average credit score of Upstart&#39;s approvals has been below the average credit score of approvals in the traditional vetting process, there&#39;s been no discernible difference in delinquency rates. Even if interest rates continue to rise rapidly, this distinction makes it more likely that financial institutions will turn to Upstart for its AI-based loan-vetting platform.</p><p>As if this weren&#39;t enough to get excited about, Upstart has also moved beyond the personal loan arena and into the auto loan origination market. The auto loan market was recently a $751 billion opportunity -- or about 6.7 times more than the personal loan market Upstart has catered to since its inception.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq Bear Market: 4 Remarkable Growth Stocks You'll Regret Not Buying on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq Bear Market: 4 Remarkable Growth Stocks You'll Regret Not Buying on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-19 08:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/18/nasdaq-bear-market-4-growth-stocks-regret-not-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This year has offered a not-so-subtle reminder to Wall Street and the investing community that stocks don't move upward in a straight line. Since hitting their all-time closing highs, the widely ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/18/nasdaq-bear-market-4-growth-stocks-regret-not-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4166":"消费信贷","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","ISRG":"直觉外科公司","BK4561":"索罗斯持仓","SQ":"Block","BK4505":"高瓴资本持仓","BK4581":"高盛持仓","BK4504":"桥水持仓","BK4142":"酒店、度假村与豪华游轮","BK4548":"巴美列捷福持仓","BK4528":"SaaS概念","BK4023":"应用软件","BK4554":"元宇宙及AR概念","UPST":"Upstart Holdings, Inc.","BK4106":"数据处理与外包服务","BK4534":"瑞士信贷持仓","BK4566":"资本集团","ABNB":"爱彼迎","BK4535":"淡马锡持仓","BK4082":"医疗保健设备","BK4543":"AI","AI":"C3.ai, Inc."},"source_url":"https://www.fool.com/investing/2022/06/18/nasdaq-bear-market-4-growth-stocks-regret-not-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2244108696","content_text":"This year has offered a not-so-subtle reminder to Wall Street and the investing community that stocks don't move upward in a straight line. Since hitting their all-time closing highs, the widely followed Dow Jones Industrial Average, benchmark S&P 500, and growth stock-fueled Nasdaq Composite (^IXIC 1.43%) have respectively tumbled by 17%, 22%, and 33%. These moves squarely put the S&P 500 and Nasdaq in a bear market.There's no question that the velocity and unpredictability of downward moves during a bear market can weigh on investors' psyche. However, it's important to note that every notable decline in the major U.S. indexes, including the Nasdaq Composite, has eventually been cleared away by a bull market. This makes corrections and bear markets the opportune time to put your money to work.With the Nasdaq tumbling, a number of innovative growth stocks now look like incredible deals. What follows are four remarkable growth stocks you'll regret not buying on the dip.BlockThe first exceptionally innovative company investors can confidently buy during the Nasdaq bear market decline is fintech stock Block (SQ 1.74%), the company formerly known as Square. Although cryptocurrency weakness could hurt Bitcoin trading revenue in the near term, and high inflation is bad news for low-income consumers, there are more than enough long-term catalysts for Block to deliver jaw-dropping growth.For more than a decade, the company's foundation has been its seller ecosystem, commonly referred to as the \"Square ecosystem.\" This is the segment that provides point-of-sale solutions, loans, and analytics to businesses to help them succeed. In 2012, just $6.5 billion in gross payment volume (GPV) was processed by the Square ecosystem. But based on the $39.5 billion in GPV in during the first quarter of 2022, the Square ecosystem is on pace for $158 billion in annual GPV.What's particularly interesting about the seller ecosystem is that it's attracting bigger businesses that have higher annualized GPVs. Since this is predominantly a fee-driven operating segment, bigger business should lead to higher gross profit.The other key for Block is digital peer-to-peer payment platform Cash App. In the four years between the end of 2017 and end of 2021, the number of monthly transacting users on Cash App soared from 7 million to north of 44 million. With the recent acquisition of buy now, pay later company Afterpay, Block has the ability to create a closed-loop payment network with its Square ecosystem.AirbnbA second remarkable growth stock that you'll be kicking yourself if you don't buy on this Nasdaq bear market decline is travel and hosting company Airbnb (ABNB 6.68%). Even with recession fears rising and inflation biting consumers' wallets hard in the short term, Airbnb has \"industry disruptor\" written all over it.To begin with, Airbnb is unquestionably a popular alternative to traditional hotels. The Airbnb marketplace provides abundant choice, with properties that often provide a lower cost and added privacy, compared to staying in a hotel in or near a major city. In 2016, the entire platform recognized 52 million total nights and experiences booked. In just the first quarter of 2022, Airbnb practically doubled this figure, with 102.1 million nights and experiences booked.Arguably the most exciting thing about Airbnb is that long-term stays are its fastest-growing category. A \"long-term stay\" is defined as a booking of 28 or more days. In the wake of the pandemic, we've witnessed workforces becoming more mobile. These remote workers seem to be Airbnb's key to sustainably growing its hosting marketplace.Additionally, the company wants a larger piece of the $8 trillion travel industry pie. Airbnb's \"experiences\" segment is working with local experts to lead travelers on adventures, and is likely just scratching the surface with regard to its partnership potential.Image source: Getty Images.Intuitive SurgicalAnother sensational growth stock investors would be wise to scoop up on the Nasdaq bear market dip is robotic-assisted surgical system developer Intuitive Surgical (ISRG 0.72%).One reason for investors to trust Intuitive Surgical over the long haul is its market dominance. When the first quarter came to a close, the company had 6,920 of its da Vinci surgical systems installed in hospitals and surgical centers worldwide. This number may not sound like a lot, but it's many times higher than those of its closest competitors. What's more, these systems are costly ($0.5 million to $2.5 million) and the training for them is time-consuming. In other words, da Vinci buyers tend to remain clients for a long time.Intuitive Surgical's razor-and-blades operating model is also designed to emphasize operating-margin growth over time. During the 2000s, most of the company's sales originated from selling its pricey, but generally low-margin, da Vinci systems. Nowadays, instruments sold with each procedure and system servicing account for the lion's share of total sales. These are higher-margin operating segments. As the company's installed base of systems grows, profits should increase at an even faster pace.There's also a long runway for da Vinci to become a standard of care in the operating room. While it's already a leader in urology and gynecology procedures, there's plenty of room for expansion in colorectal, thoracic, and general soft-tissue surgical procedures.Upstart HoldingsA fourth and final remarkable growth stock that you'll regret not buying on the dip is cloud-based lending platform Upstart Holdings (UPST 9.54%). Even though Wall Street is leery of the unproven Upstart as interest rates rise and fears of a U.S. recession grow, there are multiple aspects of the company's operating model that suggest it could thrive.Perhaps the biggest differentiator for Upstart is its artificial intelligence (AI)-powered lending platform. Rather than relying on the same vetting process for loans that financial institutions have leaned on for decades, Upstart uses AI. This led to 74% of all loans on its platform being fully automated during the first quarter. Automation ultimately saves financial institutions time and money.To build on this point, Upstart's AI-fueled lending platform is opening up opportunities for previously underbanked people. Although the average credit score of Upstart's approvals has been below the average credit score of approvals in the traditional vetting process, there's been no discernible difference in delinquency rates. Even if interest rates continue to rise rapidly, this distinction makes it more likely that financial institutions will turn to Upstart for its AI-based loan-vetting platform.As if this weren't enough to get excited about, Upstart has also moved beyond the personal loan arena and into the auto loan origination market. The auto loan market was recently a $751 billion opportunity -- or about 6.7 times more than the personal loan market Upstart has catered to since its inception.","news_type":1},"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003928423,"gmtCreate":1640856403288,"gmtModify":1676533548278,"author":{"id":"3585210989099593","authorId":"3585210989099593","name":"Charllote","avatar":"https://static.tigerbbs.com/a2496ef7bf25db8edab8d3a108e1f8e9","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3585210989099593","authorIdStr":"3585210989099593"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003928423","repostId":"2195454191","repostType":4,"repost":{"id":"2195454191","pubTimestamp":1640852195,"share":"https://ttm.financial/m/news/2195454191?lang=&edition=fundamental","pubTime":"2021-12-30 16:16","market":"us","language":"en","title":"Want $1 Million? Buy and Hold These 2 Stocks for the Next Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2195454191","media":"Motley Fool","summary":"These two stocks could provide life-changing returns in 10 years.","content":"<html><head></head><body><p>The stock market has had <a href=\"https://laohu8.com/S/AONE.U\">one</a> of its best decades ever, with the <b>SPDR S&amp;P 500 ETF</b> providing 275% returns over the past 10 years. While this performance is extremely impressive, I believe there are two stocks that could outperform the market and provide multibagger returns over the next decade.</p><p>If you add <b>Doximity</b> (NYSE:DOCS) and <b>DermTech</b> (NASDAQ:DMTK) to a diversified portfolio, they could help you turn $100,000 into $1 million over the next decade. Here&#39;s how.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31ce77a52792905dc64e60dfc5da1196\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images</span></p><h2>Doximity: A doctor&#39;s social media</h2><p>While many business professionals use <b>Microsoft</b>&#39;s LinkedIn, nearly 80% of medical professionals in the U.S. use Doximity. Doximity serves as a career growth app, a messaging app, an educational resource, and a social media platform all in one for doctors. In addition, Doximity offers telehealth accessibility, making it the super app for doctors and healthcare professionals.</p><p>Doximity has truly become a primary platform that medical professionals use. Aside from the 80% of doctors on the platform, 50% of nurse practitioners and physician assistants use it, and a staggering 90% of medical students use it -- signaling that Doximity will continue to be the place where medical workers should go to collaborate, communicate, and expand their careers. As a result, Doximity&#39;s platform has attracted lots of advertisers.</p><p>Doximity makes money from advertising revenue from pharmaceutical companies looking to show doctors their drugs on the research part of its app that delivers personalized news and research to doctors. Over 600 pharmaceutical companies are desperate to get their products in front of doctors and potential buyers, 200 of which spend over $100,000 per year to do so. What is most impressive is that Doximity&#39;s net retention rate is 173% -- meaning these customers spent 73 cents more in Q3 2021 on top of every dollar they spent in the year-ago quarter, including churning customers.</p><p>In addition, 93% of Doximity&#39;s revenue comes from subscriptions from pharmaceutical companies. Because of this focus on subscriptions, its gross margins are a lofty 89%. Another factor making this company a financial powerhouse is the 80% share of U.S, doctors already on the platform, which means Doximity does not have to spend a ton on operating expenses. This allows for Doximity to bring tons of cash to the bottom line: In Q3, it had $36 million in net income -- representing 45% of revenue. And as if this couldn&#39;t get any better, the company also generated $18 million in free cash flow in Q3.</p><p>In addition to this impressive profitability, the company has been able to consistently grow its top line at 76% year over year. It&#39;s not hard to see why shares trade at a staggering 184 times earnings and 36 times sales. However, this company has a dominant foothold in this market, with the majority of its consumer base on the platform, making advertising space nearly invaluable. This position has already led to growth and profitability, that I think could continue for the next decade.</p><h2>DermTech: A different approach to skin cancer</h2><p>DermTech is riskier than Doximity, but its growth potential is even larger. DermTech has created a new way to test for skin cancer that is easier, cheaper, and more accurate than the traditional biopsy. Instead of having a chunk of skin taken out, DermTech&#39;s PLA Test can simply be put on the area of concern like a bandage, and results are given within 72 hours. The chance of missing melanoma drops from 17% to 1% with DermTech.</p><p>Where DermTech has major growth potential is with its insurance coverage. While the company&#39;s product is not currently insured by the big insurance companies, it expects to obtain coverage in late 2022 or early 2023. If the company can get major insurance coverage, that could make it easier for doctors to switch over to its product.</p><p>Even without major coverage, the company is seeing impressive growth. Test revenue grew 140% year over year, and the company&#39;s sample volume reached 11,720, growing 75% year over year in Q3.</p><p>The company is nowhere near profitability, having lost almost seven times its revenue in Q3, but with just a $485 million market capitalization, it would be unrealistic to expect profitability at this stage. DermTech does, however, have over $204 million in cash and cash equivalents to subsidize its losses for some time. The company has only brought in $8.7 million in 2021, yet it has a market opportunity of over $10 billion. With such a large opportunity and a superior product, it is understandable that the company is valued at 40 times sales.</p><p>While its current valuation and unprofitability aren&#39;t appealing, the company could potentially grow its revenue by 100 times and still be scratching the surface of its addressable market. With this much potential, adding DermTech into a diversified portfolio could be a move that -- if it plays out -- could create portfolio-changing (and life-changing) results.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million? Buy and Hold These 2 Stocks for the Next Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million? Buy and Hold These 2 Stocks for the Next Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 16:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/29/want-1-million-buy-and-hold-these-2-stocks-for-the/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market has had one of its best decades ever, with the SPDR S&P 500 ETF providing 275% returns over the past 10 years. While this performance is extremely impressive, I believe there are two ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/29/want-1-million-buy-and-hold-these-2-stocks-for-the/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","DOCS":"Doximity, Inc.","BK4539":"次新股","BK4551":"寇图资本持仓","BK4167":"医疗保健技术"},"source_url":"https://www.fool.com/investing/2021/12/29/want-1-million-buy-and-hold-these-2-stocks-for-the/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2195454191","content_text":"The stock market has had one of its best decades ever, with the SPDR S&P 500 ETF providing 275% returns over the past 10 years. While this performance is extremely impressive, I believe there are two stocks that could outperform the market and provide multibagger returns over the next decade.If you add Doximity (NYSE:DOCS) and DermTech (NASDAQ:DMTK) to a diversified portfolio, they could help you turn $100,000 into $1 million over the next decade. Here's how.Image source: Getty ImagesDoximity: A doctor's social mediaWhile many business professionals use Microsoft's LinkedIn, nearly 80% of medical professionals in the U.S. use Doximity. Doximity serves as a career growth app, a messaging app, an educational resource, and a social media platform all in one for doctors. In addition, Doximity offers telehealth accessibility, making it the super app for doctors and healthcare professionals.Doximity has truly become a primary platform that medical professionals use. Aside from the 80% of doctors on the platform, 50% of nurse practitioners and physician assistants use it, and a staggering 90% of medical students use it -- signaling that Doximity will continue to be the place where medical workers should go to collaborate, communicate, and expand their careers. As a result, Doximity's platform has attracted lots of advertisers.Doximity makes money from advertising revenue from pharmaceutical companies looking to show doctors their drugs on the research part of its app that delivers personalized news and research to doctors. Over 600 pharmaceutical companies are desperate to get their products in front of doctors and potential buyers, 200 of which spend over $100,000 per year to do so. What is most impressive is that Doximity's net retention rate is 173% -- meaning these customers spent 73 cents more in Q3 2021 on top of every dollar they spent in the year-ago quarter, including churning customers.In addition, 93% of Doximity's revenue comes from subscriptions from pharmaceutical companies. Because of this focus on subscriptions, its gross margins are a lofty 89%. Another factor making this company a financial powerhouse is the 80% share of U.S, doctors already on the platform, which means Doximity does not have to spend a ton on operating expenses. This allows for Doximity to bring tons of cash to the bottom line: In Q3, it had $36 million in net income -- representing 45% of revenue. And as if this couldn't get any better, the company also generated $18 million in free cash flow in Q3.In addition to this impressive profitability, the company has been able to consistently grow its top line at 76% year over year. It's not hard to see why shares trade at a staggering 184 times earnings and 36 times sales. However, this company has a dominant foothold in this market, with the majority of its consumer base on the platform, making advertising space nearly invaluable. This position has already led to growth and profitability, that I think could continue for the next decade.DermTech: A different approach to skin cancerDermTech is riskier than Doximity, but its growth potential is even larger. DermTech has created a new way to test for skin cancer that is easier, cheaper, and more accurate than the traditional biopsy. Instead of having a chunk of skin taken out, DermTech's PLA Test can simply be put on the area of concern like a bandage, and results are given within 72 hours. The chance of missing melanoma drops from 17% to 1% with DermTech.Where DermTech has major growth potential is with its insurance coverage. While the company's product is not currently insured by the big insurance companies, it expects to obtain coverage in late 2022 or early 2023. If the company can get major insurance coverage, that could make it easier for doctors to switch over to its product.Even without major coverage, the company is seeing impressive growth. Test revenue grew 140% year over year, and the company's sample volume reached 11,720, growing 75% year over year in Q3.The company is nowhere near profitability, having lost almost seven times its revenue in Q3, but with just a $485 million market capitalization, it would be unrealistic to expect profitability at this stage. DermTech does, however, have over $204 million in cash and cash equivalents to subsidize its losses for some time. The company has only brought in $8.7 million in 2021, yet it has a market opportunity of over $10 billion. With such a large opportunity and a superior product, it is understandable that the company is valued at 40 times sales.While its current valuation and unprofitability aren't appealing, the company could potentially grow its revenue by 100 times and still be scratching the surface of its addressable market. With this much potential, adding DermTech into a diversified portfolio could be a move that -- if it plays out -- could create portfolio-changing (and life-changing) results.","news_type":1},"isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}